戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 associated with combined use of a VKA and an antiplatelet drug.
2 e aged 18 years or older, and were taking an antiplatelet drug.
3 l haemorrhage is increased for people taking antiplatelet drugs.
4 mal inhibitory concentrations for a panel of antiplatelet drugs.
5  the ensuing thrombosis) relative to current antiplatelet drugs.
6  are concerns with ticagrelor, as with other antiplatelet drugs.
7 nticoagulants (OAC) and 762 (28.6%) received antiplatelet drugs.
8 nt brain ischaemia more effectively than are antiplatelet drugs.
9  have emerged, establishing a need for novel antiplatelet drugs.
10 A) alleles showed increased sensitivity to 2 antiplatelet drugs.
11  standard heparin may potentiate efficacy of antiplatelet drugs.
12 % vs 16.1%, p < 0.001) as well as the use of antiplatelet drugs.
13 r therapy with a vitamin K antagonist and an antiplatelet drug, 1.28 (95% CI, 1.13-1.44) for therapy
14 erapy of a direct oral anticoagulant with an antiplatelet drug, 3.73 (95% CI, 3.23-4.31) for vitamin
15 biopsies (328 low-dose aspirin, 73 full-dose antiplatelet drugs, 51 direct oral anticoagulants, 36 wa
16 for the use of statins, BBs, ACEIs/ARBs, and antiplatelet drugs after discharge completely eliminated
17 ver, the benefits associated with the use of antiplatelet drugs also come with a risk of bleeding com
18                                        A new antiplatelet drug and a number of trials involving HMG C
19 ergoing CABG with the individual OMT agents, antiplatelet drug and statin, at 5 years had lower 10-ye
20 telets are less responsive to the effects of antiplatelet drugs and contain messenger ribonucleic aci
21  use of thrombolytic agents, anticoagulants, antiplatelet drugs and neuroprotective agents in acute s
22 junctive therapies, such as corticosteroids, antiplatelet drugs and other immunosuppressive agents of
23 re, thrombolytics during, and beta-blockers, antiplatelet drugs, and angiotensin-converting-enzyme (A
24  the evidence for the efficacy and safety of antiplatelet drugs, and to provide practicing cardiologi
25 prised prescription fills for beta-blockers, antiplatelet drugs, angiotensin-converting enzyme inhibi
26                                              Antiplatelet drug (APD) therapy is the cornerstone for t
27                                  Concomitant antiplatelet drugs appeared to increase the risk for maj
28 te certain neoplastic malignancies; however, antiplatelet drugs are still not part of routine pharmac
29 schemic agents (nitrates and beta blockers), antiplatelet drugs (aspirin, P2Y(12), and glycoprotein I
30  the concept of changing the type or dose of antiplatelet drugs based on the result of platelet funct
31 r and stereoselective total synthesis of the antiplatelet drug beraprost in only 8 steps from a key e
32 l individual pharmacological agents, such as antiplatelet drugs, beta-blockers, ACE inhibitors, and l
33 inhibitors or angiotensin receptor blockers, antiplatelet drugs, beta-blockers, and statins on all-ca
34 alpha and IL-1B are better suppressed by the antiplatelet drug Brilinta (r(2) = 0.30, p < 0.0001) but
35 port the inhibition of GPR17 by the marketed antiplatelet drugs cangrelor and ticagrelor, previously
36                                          The antiplatelet drug clopidogrel is a new thienopyridine de
37 nistration of FXI ASO with enoxaparin or the antiplatelet drug clopidogrel produced improved antithro
38 standard 75-mg daily maintenance dose of the antiplatelet drug clopidogrel.
39 , structures of 2B4 were determined with the antiplatelet drugs clopidogrel and ticlopidine, which we
40 acid (pCMBS) and the active metabolites from antiplatelet drugs, clopidogrel and CS-747, inactivate t
41      Moreover, the effect is unresponsive to antiplatelet drugs commonly used.
42 n of antithrombotic therapy with more potent antiplatelet drugs, dual antiplatelet therapy, or vitami
43 -two (10.6%) patients interrupted at least 1 antiplatelet drug during the first year after DES implan
44 age to desmopressin or placebo to reduce the antiplatelet drug effect.
45                               Measurement of antiplatelet drug efficacy with a point-of-care device a
46 may have therapeutic advantages as potential antiplatelet drugs for patients with high plasma Galecti
47            In a stability analysis excluding antiplatelet drugs from the exposure definition, more me
48                   The biological response to antiplatelet drugs has repeatedly been shown to predict
49 el was compatible with reduced mortality for antiplatelet drugs (hazard ratio [HR], 0.86; 95% CI, 0.7
50 al platelet reactivity during treatment with antiplatelet drugs, higher rates of adverse cardiovascul
51 Y12 inhibitors are among the most successful antiplatelet drugs, however, show remarkable variability
52                     This study supports that antiplatelet drugs improve survival and beta-blockers de
53 with a previous ICH treated with warfarin or antiplatelet drugs in comparison with no antithrombotic
54     The relative safety and efficacy of some antiplatelet drugs in women has been disputed.
55                               Currently used antiplatelet drugs, including aspirin and ticlopidine, a
56                              A number of new antiplatelet drugs, including clopidogrel and the glycop
57 ements in surgical technique; more effective antiplatelet drugs; increasingly intensive risk factor m
58 logically important compounds, including the antiplatelet drug indobufen.
59                                              Antiplatelet drugs induce only a moderate relative risk
60 al anticoagulants and the recently developed antiplatelet drugs is a great challenge for transplant t
61 h established CAD, secondary prevention with antiplatelet drugs is an asset of pharmacological strate
62 e diphosphate receptor P2Y12, the target for antiplatelet drugs like clopidogrel, facilitates delayed
63 est when a VKA was used concurrently with an antiplatelet drug (low-dose aspirin and a VKA: 3.6% of c
64 troke, or myocardial infarction treated with antiplatelet drugs (mainly aspirin based, without routin
65 quences in influenza virus pathogenesis, and antiplatelet drugs might be explored to develop new anti
66 , the method was applied to the synthesis of antiplatelet drug n-butyl phthalide and cytotoxic agonis
67 esent treatment is based on a combination of antiplatelet drugs, optimisation of blood pressure and L
68 mportant for patients who take warfarin with antiplatelet drugs or nonselective nonsteroidal anti-inf
69 ctive effect for warfarin patients not using antiplatelet drugs or NSAIDs (HR, 0.86; 95% CI, 0.70-1.0
70            Among patients concurrently using antiplatelet drugs or NSAIDs, those without PPI co-thera
71 t reduction occurred in patients also taking antiplatelet drugs or NSAIDs.
72         The findings suggest applications of antiplatelet drugs or TP receptor antagonists for the tr
73  95% CI: 1.28, 3.3; P = .003), and full-dose antiplatelet drugs (OR, 2.5; 95% CI: 1.29, 5.0; P = .007
74 psy hematomas were associated with full-dose antiplatelet drugs, patient age, and 9-gauge or larger n
75 is prototype can act as a real-time assay of antiplatelet drug pharmacokinetics.
76              Aspirin is the most widely used antiplatelet drug postmyocardial infarction, yet its opt
77 ment options now include the next-generation antiplatelet drugs prasugrel and ticagrelor, and, in ter
78 enetic test results significantly influenced antiplatelet drug prescribing; however, almost half of C
79 ay competing risk models (sex, age, smoking, antiplatelet drugs, previous vascular disease, diabetes
80                                              Antiplatelet drugs provide first-line antithrombotic the
81 diovascular outpatients participating in the Antiplatelet Drug Resistances and Ischemic Events (ADRIE
82 hough the gold standard definition to assess antiplatelet drug response has not been fully establishe
83                                   Biological antiplatelet drug responsiveness, measured with specific
84 bility and clinical application prospects of antiplatelet drug reversal agents, offering a promising
85 roup) or no genotyping (usual care) to guide antiplatelet drug selection.
86 lishment of a PFT therapeutic range for each antiplatelet drug should be considered and is discussed.
87 ngiotensin-converting enzyme inhibition, and antiplatelet drugs significantly reduce the risk of card
88 nation of 4 types of medications: at least 1 antiplatelet drug, statin, angiotensin-converting enzyme
89 was defined as the combination of at least 1 antiplatelet drug, statin, beta-blocker, and angiotensin
90                                              Antiplatelet drugs such as aspirin and P2Y12 inhibitors
91       Although it has been demonstrated that antiplatelet drugs suppress the growth of abdominal aort
92 eactivity (PR) phenotypes may identify novel antiplatelet drug targets.
93 cal trials of four members of a new class of antiplatelet drugs, the GPIIb-IIIa blockers, targeted at
94 e us in appropriate use of antithrombotic or antiplatelet drug therapy to decrease the risk of events
95 s the feasibility of randomising patients on antiplatelet drug therapy with spontaneous intracerebral
96 ond 6 months, possibly because of inadequate antiplatelet drug therapy.
97 n patients with intracerebral haemorrhage on antiplatelet drug therapy.
98  in these concentrations upon treatment with antiplatelet drugs, thereby verifying the direct efficac
99                   The effect of adding other antiplatelet drugs to aspirin for long-term secondary pr
100 ous intracerebral haemorrhage who are taking antiplatelet drugs to desmopressin or placebo.
101 , be considered for the development of novel antiplatelet drugs to fight cardiovascular diseases in h
102 inal tenderness, blood pressure <=100 mm Hg, antiplatelet drug use (nonaspirin), albumin <3.0 g/dL, d
103                       Among patients in whom antiplatelet drug use was discontinued at least 2 days b
104 yridine administration and with inconsistent antiplatelet drug use within 30 days.
105                                              Antiplatelet drugs were used less frequently (24.7% vs 2
106 isk patients, taking both anticoagulants and antiplatelet drugs when topical anesthesia is administer
107 domized trials to guide perioperative use of antiplatelet drugs, which affect the risk of both bleedi
108 oring of platelet function and the effect of antiplatelet drugs will improve outcomes in cardiovascul

 
Page Top